Status:

TERMINATED

Effect of Chronic Inflammation on Myocardial Perfusion and Function

Lead Sponsor:

National Heart, Lung, and Blood Institute (NHLBI)

Conditions:

Psoriasis

Eligibility:

All Genders

18+ years

Brief Summary

Background: Heart failure (HF) is a public health burden. Studies have shown a link between inflammation, myocardial dysfunction, and HF. Researchers want to use psoriasis as a disease model of chron...

Detailed Description

Study Description: Heart failure (HF) remains a significant public health burden despite expanding and improving treatment options. Clinical and pre-clinical studies have demonstrated compelling rela...

Eligibility Criteria

Inclusion

  • INCLUSION CRITERIA:
  • Subjects of both genders will be considered for inclusion in this study. There will be no racial, ethnic, or gender discrimination.
  • Affected Subjects:
  • 18 years of age or older
  • Diagnosed with moderate-severe psoriasis clinically confirmed by a licensed physician, or advanced practitioner consisting of typical skin findings and/or associated findings of systemic disease of joints, nails, and hair and may be scheduled to initiate biologic
  • treatment for psoriasis
  • Healthy Controls:
  • Females and males 18 years of age or older
  • EXCLUSION CRITERIA:
  • Affected Subjects:
  • Pregnant or lactating women
  • Subjects with a contraindication to MRI scanning will not receive the CMR assessment.
  • These contraindications include subjects with the following devices:
  • i. Central nervous system aneurysm clips
  • ii. Implanted neural stimulator
  • iii. Implanted cardiac pacemaker or defibrillator
  • iv. Cochlear implant
  • v. Ocular foreign body (e.g. metal shavings)
  • vi. Implanted Insulin pump
  • vii. Metal shrapnel or bullet
  • viii. Estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73m\^2 body surface area according to the Modification of Diet in Renal Disease criteria
  • History of seizures or taking anti-epileptic medications
  • Inability to provide informed consent
  • Healthy Controls:
  • Diagnosis of inflammatory disease (including psoriasis, psoriatic arthritis, rheumatoid arthritis, lupus, inflammatory bowel disease)
  • Pregnant women and lactating women
  • Subjects with a contraindication to MRI scanning will not receive the CMR assessment.
  • These contraindications include subjects with the following devices:
  • ix. Central nervous system aneurysm clips
  • x. Implanted neural stimulator
  • xi. Implanted cardiac pacemaker or defibrillator
  • xii. Cochlear implant
  • xiii. Ocular foreign body (e.g. metal shavings)
  • xiv. Implanted Insulin pump
  • xv. Metal shrapnel or bullet
  • xvi. Estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73m\^2 body surface area according to the Modification of Diet in Renal Disease criteria
  • History of seizures or taking anti-epileptic medications
  • Inability to provide informed consent

Exclusion

    Key Trial Info

    Start Date :

    June 7 2021

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    May 18 2022

    Estimated Enrollment :

    16 Patients enrolled

    Trial Details

    Trial ID

    NCT04870827

    Start Date

    June 7 2021

    End Date

    May 18 2022

    Last Update

    April 6 2023

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    National Institutes of Health Clinical Center

    Bethesda, Maryland, United States, 20892